Bariatric Surgery Tops Usual Care in Type 2 Diabetes Bariatric Surgery Tops Usual Care in Type 2 Diabetes
Combined data from four randomized clinical trials showed ongoing lower A1c levels, diabetes medication use, and diabetes remission rates at 7 years.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 27, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
Theradaptive to Expand Global Clinical Trials After Receiving Full Ethics Approval in Australia for OsteoAdapt SP
Theradaptive can now enroll patients at each site in Australia listed with Bellberry as part of its global clinical study for OsteoAdapt SP. FREDERICK, Md., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Theradaptive, a market leader in targeted regenerative therapeutics, has received full ethics... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 27, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Novel Biotherapeutic to Be Tested in Ulcerative Colitis Novel Biotherapeutic to Be Tested in Ulcerative Colitis
An investigational combination of eight strains of bacteria known collectively as MB310 — a live biotherapeutic product — is due to start its first clinical trial in ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 26, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Renowned Thoracic Surgeon Enhances Mesothelioma Care in FL
Dr. Rodney Landreneau is joining the renowned Thoracic Surgical Program at Tampa General Hospital. He spent decades caring for patients with pleural mesothelioma and lung cancer patients in Western Pennsylvania at the University of Pittsburgh and Penn Highlands Healthcare. He’s now moved more than 1,000 miles to help augment Tampa General Hospital Cancer Institute’s successful patient care.
Landreneau has nearly 40 years of experience treating malignant pleural mesothelioma and lung cancer, as well as benign and malignant diseases of the esophagus. An internationally recognized scientific investigator in the treatme...
Source: Asbestos and Mesothelioma News - February 26, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Cancer Center Doctors/Specialists Mesothelioma Treatment Source Type: news
5 dental products that caught my eye at Chicago Midwinter 2024
The 2024 Chicago Midwinter Meeting did not disappoint. Personally, I thought the show had the same buzz and energy around it and during it as the Midwinter meetings before the pandemic. It also continued a strong start for trade shows I have attended (Rocky Mountain Dental Convention and Yankee Dental Congress before Chicago), signaling perhaps that this is the year that trade shows bounce back to the way we in the dental industry remember them before COVID-19.I spent all three days of the meeting walking the show floor and talking to vendors about what they believed was important to readers of DrBicuspid.com. More of that...
Source: AuntMinnie.com Headlines - February 26, 2024 Category: Radiology Authors: Kevin Henry Tags: Hygiene Tools Industry Updates Podcasts Source Type: news
Stock Up 14% Today?
ALT stock is up thanks to news from Zealand Pharma Altimmune (NASDAQ:ALT) stock is rising higher on Monday but it’s not actually due to any news from the clinical-stage biopharmaceutical company. Instead, a clinical trial update from rival Zealand Pharma is behind the increase in ALT stock today.…#zealandpharma #alt #intuitivemachines #freighttechnologies #williamwhite (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2024 Category: Consumer Health News Source Type: news
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. LUMO, a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market…#austin #lumospharma #pghd #phase2 #thisregistrationlink #pin #thiswebcastlink #investorsmedia (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2024 Category: Consumer Health News Source Type: news
New Experimental Drug, Rusfertide, Could Be Big Advance Against Rare Blood Cancer
MONDAY, Feb. 26, 2024 -- Polycythemia vera is a rare form of blood cancer with few good treatment options, but that may soon change based on the results of a new clinical trial.
An injected experimental drug called rusfertide appears effective in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news
New Drug Could Be Big Advance Against Rare Blood Cancer
MONDAY, Feb. 26, 2024 -- Polycythemia vera is a rare form of blood cancer with few good treatment options, but that may soon change based on the results of a new clinical trial.An injected experimental drug called rusfertide appears effective in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news
Global trends in R & D 2024: activity, productivity, and enablers
This report assesses the trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. The notable acceleration and adaptability of the innovation ecosystem is examined in terms of several enablers of R&D productivity, including the relationship between shortening trial durations and the ‘white space’ within clinical development timelines that have been reducing for some diseases and increasing for ot...
Source: The Kings Fund - Health Management Specialist Collection - February 26, 2024 Category: Health Management Authors: The King ' s Fund Library Tags: NHS performance and productivity Source Type: news
Making the most of missing data - Kilpatrick R, Greenberg RG.
Clinical trials are demanding, resource intensive, and essential to the health and well-being of children. In this issue of Pediatrics, Li and colleagues1 outline the magnitude of an often-overlooked problem within neonatal and perinatal clinical trials. T... (Source: SafetyLit)
Source: SafetyLit - February 26, 2024 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Long-Term Ixekizumab Use Shows Solid Safety Data Long-Term Ixekizumab Use Shows Solid Safety Data
Final safety results from 25 randomized clinical trials were consistent with previous reports at up to 6 years ' follow-up.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 26, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Immunize your portfolio from the uneventful While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum. This is a good time to remind you…#biotechpenny #boston #massachusetts #adicetbio #grandviewresearch #stoketherapeutics #rna #tango #stoke #dravet (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2024 Category: Consumer Health News Source Type: news
